All In Biotech

Drug Trial Radar · NCT05002569

A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma

A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy With Nivolumab + Relatlimab Fixed-dose Combination Versus Nivolumab Monotherapy After Complete Resection of Stage III-IV Melanoma

Last checked: Nov 19, 2026Latest source record: Jan 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,093 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

1,093

Actual

Start

Oct 19, 2021

Primary completion

Dec 16, 2024

Study completion Apr 2, 2025

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Aug 12, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess nivolumab plus relatlimab fixed-dose combination (FDC) versus nivolumab alone in participants with completely resected stage III-IV melanoma.

Conditions

  • Melanoma

Interventions

  • NivolumabBiological

    Specified dose on specified days

  • Nivolumab + Relatlimab Fixed Dose CombinationBiological

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recurrence Free Survival (RFS)Time frame: Approximately 27.5 Months

Locations

184 sites in 25 countries. Site status is shown where the registry gives one.

  • Local Institution - 0176

    Birmingham, Alabama

  • Local Institution - 0164

    Springdale, Arkansas

  • Local Institution - 0200

    Los Angeles, California

  • Local Institution - 0185

    Palo Alto, California

  • Local Institution - 0162

    San Francisco, California

  • Saint John's Cancer Institute

    Santa Monica, California

  • Local Institution - 0138

    Aurora, Colorado

  • Local Institution - 0166

    Washington D.C., District of Columbia

  • Local Institution - 0243

    Miami, Florida

  • Washington University School Of Medicine

    Miami, Florida

  • Local Institution - 0179

    Pensacola, Florida

  • Moffitt Cancer Center, Richard M. Shulze Family Foundation Outpatient Center

    Tampa, Florida

  • Local Institution - 0191

    Atlanta, Georgia

  • Local Institution - 0148

    Atlanta, Georgia

  • Local Institution - 0202

    Chicago, Illinois

  • Local Institution - 0177

    Peoria, Illinois

  • Local Institution - 0223

    Fort Wayne, Indiana

  • University of Iowa-Holden Comprehensive Cancer Center

    Iowa City, Iowa

  • Local Institution - 0178

    Westwood, Kansas

  • Dana-Farber Cancer Institute-Melanoma

    Boston, Massachusetts

  • Local Institution - 0258

    Ann Arbor, Michigan

  • Local Institution

    Grand Rapids, Michigan

  • Local Institution - 0133

    Minneapolis, Minnesota

  • Local Institution - 0139

    Hackensack, New Jersey

  • Local Institution - 0206

    Morristown, New Jersey

  • Local Institution - 0140

    New York, New York

  • Icahn School Of Medicine At Mount Sinai

    New York, New York

  • Local Institution - 0210

    New York, New York

  • Local Institution - 0130

    Charlotte, North Carolina

  • Local Institution - 0145

    Durham, North Carolina

  • MetroHealth Medical Center

    Cleveland, Ohio

  • Local Institution - 0141

    Cleveland, Ohio

  • The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C

    Columbus, Ohio

  • Local Institution - 0267

    Allentown, Pennsylvania

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • Local Institution - 0125

    Pittsburgh, Pennsylvania

  • Local Institution - 0171

    Charleston, South Carolina

  • Local Institution - 0147

    Germantown, Tennessee

  • Local Institution - 0183

    Nashville, Tennessee

  • Local Institution - 0146

    Austin, Texas

Showing 40 of 184 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.